Live Breaking News & Updates on Pathogenetic Mechanisms

Stay updated with breaking news from Pathogenetic mechanisms. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

BREAKTHROUGH IN DIGITAL HEALTH: WITHINGS HEALTH SOLUTIONS LAUNCHES BODY PRO 2, REVOLUTIONIZING THE DETECTION OF EARLY DIABETES COMPLICATIONS WITH THE NEXT-GEN CELLULAR SCALE

/PRNewswire/ Today, on World Diabetes Day, Withings Health Solutions provides a leap forward for the digital health industry with the launch of Body Pro 2,. ....

United States , Kelley Newlin Lew , Amit Goel , Angelica Carbajal Ram , Eric Carreel , Patriciam Kluding , Jesse Pocuis , Deepak Menon , Triantafyllos Didangelos , Johnr Singleton , A Gordon Smith , Antoine Robiliard , Raffaele Galiero , Clinical Nursing Research , Diabetes Technology Therapeutics , Personalized Health Nudges , Withings Health Solutions , International Journal Of Molecular Sciences , World Diabetes Day , Health Solutions , Body Pro , Diabetes Day , Electrochemical Skin Conductance , Diabetic Peripheral Neuropathies , Withings Health , Health Nudges ,

Health Canada approves Zolgensma®, the one-time gene therapy for pediatric patients with spinal muscular atrophy (SMA)

Share this article

SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2
2,3
Zolgensma (onasemnogene abeparvovec) is approved for the treatment of pediatric SMA patients with 3 or fewer copies of the SMN2 gene, or infantile-onset SMA
1
Zolgensma is designed to address the genetic root cause of SMA by replacing the missing or defective SMN1 gene to halt disease progression
1
DORVAL, QC, Dec. 16, 2020 /CNW/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Zolgensma
® (onasemnogene abeparvovec) an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 ( ....

City Of , United Kingdom , British Columbia , Nicolas Chrestian , Susi Vander Wyk , Julie Schneiderman , Hugh Mcmillan , Andrea Marazzi , Canadian Pharmaceutical Alliance , Novartis Pharmaceuticals Canada , National Organization For Rare Disorders , Novartis Pharmaceuticals Canada Inc , Health Canada , Centre Hospitalier , Pediatric Neurologist , Eastern Ontario , Paediatric Neurology , Enfant Soleil , Executive Director , Country Head , Novartis Pharmaceuticals , Quebec City , Gene Therapy , Pharmaceuticals Canada Inc , Novartis Gene , Gene Therapies ,